Douglas Michael Sproule MD
Assistant Professor of Neurology, Columbia University Medical Center
Join to View Full Profile
180 Fort Washington AveFl 5New York, NY 10032
Phone+1 212-342-3679
Dr. Sproule is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Child Neurology, 2005 - 2008- New York Presbyterian Hospital (Columbia Campus)Residency, Child Neurology, 2003 - 2006
Tower Health/St. Christopher's Hospital for ChildrenResidency, Pediatrics, 2003 - 2005
Columbia University Vagelos College of Physicians and SurgeonsClass of 2003
Certifications & Licensure
NY State Medical License 2005 - 2027
MA State Medical License 2013 - 2014
American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology- American Board of Psychiatry and Neurology Neuromuscular Medicine
Clinical Trials
- Clinical Study of Spinal Muscular Atrophy Start of enrollment: 2005 May 01
- Giant Axonal Neuropathy Natural History Study Start of enrollment: 2011 Dec 01
Publications & Presentations
PubMed
- 58 citationsBiodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue.Gretchen Thomsen, Arthur H.M. Burghes, Caroline Hsieh, Janet Do, Binh T. T. Chu
Nature Medicine. 2021-10-01 - 218 citationsOnasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, ...John W. Day, Richard S. Finkel, Claudia A. Chiriboga, Anne M. Connolly, Thomas O. Crawford
The Lancet. Neurology. 2021-04-01 - 31 citationsAn updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for ...Rebecca Dean, Ivar Jensen, Phil Cyr, Beckley Miller, Benit Maru
Journal of Market Access & Health Policy. 2021-02-28
Press Mentions
- BridgeBio Pharma to Present Preliminary Findings on Its Novel Bioassay Measuring Glycosylated Alpha-Dystroglycan (⍺DG) in Patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)March 17th, 2023
- BridgeBio Pharma (BBIO) Reports 12-Month Results from Phase 2 Study of BBP-418October 14th, 2022
Dosing Begins in Phase 2 Trial Testing Oral Therapy BBP-418 for LGMD2iMarch 2nd, 2021- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
